

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

DALRADA FINANCIAL CORPORATION

A Delaware Corporation

600 La Terraza Blvd.

Escondido, CA 92025

949-689-0612

Website: www.dalrada.com

Email: inquiries@dalrada.com

SIC Code: 8721

Annual Report For the Period Ending: June 30, 2020 (the "Reporting Period")

As of June 30, 2020, the number of shares outstanding of our Common and Preferred Stock was:

Common: 68,464,742 Preferred: 5,000

As of March 31, 2020, the number of shares outstanding of our Common and preferred Stock was:

Common: 63,999,128 Preferred: 5,000

As of June 30, 2019, the number of shares outstanding of our Common and preferred Stock was:

Common: 48,281,128 Preferred: 0

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No: (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities and the dates of the name changes.

Current Name: Dalrada Financial Corporation – since April 2, 2004
Imaging Technologies Corporation – Since May 1995
Principal Computer Products, Inc. – May 12, 1983

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable)
Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Dalrada Financial Corporation ("DFCO") is a Wyoming corporation.

Current state of Incorporation: Wyoming – May 5, 2020 – In good Standing

Original state of Incorporation: Delaware - May, 12, 1983

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

2) Security Information

Trading symbol:	DFCO
Exact title and class of securities outstanding:	Common
CUSIP:	45244U401
Par or stated value:	\$.005
Total shares authorized:	1,000,000,000 as of date: 06-30-2020
Total shares outstanding:	68,464,742 as of date: 06-30-2020
Number of shares in the Public Float ² :	37,134,987 as of date: 06-30-2020
Total number of shareholders of record:	551 as of date: 03-31-2020

Additional class of securities (if any):

Trading symbol:	n/a
Exact title and class of securities outstanding:	Preferred
CUSIP:	n/a
Par or stated value:	\$.01
Total shares authorized:	100,000 as of date: 06-30-2020
Total shares outstanding:	5,000 as of date: 06-30-2020

Transfer Agent:

Name: Standard Register and Transfer company, Inc.
440 E 400 S Suite 200
Salt Lake City, UT 84111
Phone: (801) 571-8844

Email: support@standardregistrar.com

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

In May 2019 Dalrada Health Products Corp. acquired a new subsidiary, C2C Life Sciences, Inc. C2C Life Sciences, Inc. On November 1, 2019, the acquisition was rescinded. Such rescission has been reflected in these financials.

On December 6, 2019, Dalrada, via its wholly owned subsidiary, Dalrada Precision, acquired, by stock exchange agreement, 100% of Likido Ltd. (HQ) ("Likido") in exchange of 6,118,000 shares of the Company's common stock. Likido, a United Kingdom engineering-design company, is based in Edinburgh, Scotland. Likido is an international technology company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications.

On January 9, 2020, DFCO purchased seventy two percent (72%) of the issued and outstanding common equity shares of Prakat Solutions Inc. a Texas corporation, ("Prakat"). The purchase was made by means of a Stock Purchase Agreement ("SPA"). The consideration for the share purchase was three million six hundred thousand, (3,600,000) common equity shares of DFCO. Prakat has a wholly owned subsidiary based in India, Prakat Solutions Private Limited, which provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.

On March 23, 2020, via its wholly owned subsidiary, Dalrada Health Products, acquired 100% of the issued and outstanding common equity shares of Shark Innovation Technologies Corporation, a Texas corporation. The purchase was made by means of a Stock Purchase Agreement ("SPA"). The consideration for the share purchase was three million (3,000,000) common equity shares of DFCO. Sharks current business is selling and providing disinfectant spray service consisting of alcohol-free sanitization products, such as hand sanitizers and cleansing soaps to all-purpose surface cleaners and sprays that deliver effective, long-lasting protection while eliminating up to 99.99% of harmful bacteria, germs, viruses, bio-films and spores.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Shares outstanding as of Second Most Recent Fiscal Year End.									
<u>Opening Balance:</u>									
6/30/2018		Common: 47,281,128 Preferred: 0							
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
5/7/2019	New Issuance	1,000,000	Common	0.0380	no	Sandra DiCocco	Investment in subsidiary	Restricted	Exempt
Balance 06/30/19: Common		48,281,128							
12/6/2019	New Issuance	6,118,000	Common	0.0448	no	Stuart Cox	Likido Acquisition	Restricted	Exempt
2/4/2020	New Issuance	3,000,000	Common	0.0448	no	Fawad Nisar	Employment Aghreement	Restricted	Exempt
2/4/2020	New Issuance	1,430,435	Common	0.0448	no	Anuradha Bishwa	Acquired shares of Prakat, Inc.	Restricted	Exempt
2/4/2020	New Issuance	712,759	Common	0.0448	no	Abhik Biwas	Acquired shares of Prakat, Inc.	Restricted	Exempt
2/4/2020	New Issuance	552,612	Common	0.0448	no	Shikant Krish	Acquired shares of Prakat, Inc.	Restricted	Exempt
2/4/2020	New Issuance	329,478	Common	0.0448	no	Spihart K. Reddy	Acquired shares of Prakat, Inc.	Restricted	Exempt
2/4/2020	New Issuance	292,884	Common	0.0448	no	Rajnish Kumar Thaurk	Acquired shares of Prakat, Inc.	Restricted	Exempt
2/4/2020	New Issuance	281,832	Common	0.0448	no	Vijayendra Anil Kumar	Acquired shares of Prakat, Inc.	Restricted	Exempt
3/23/2020	New Issuance	3,000,000	Common	0.0448	no	Gregg Silvers	Acquired shares of Shark Innovative Technologies	Restricted	Exempt
Balance 03/30/20: Common		63,999,128							
4/13/2020	New Issuance	3,965,614	Common	0.0490	no	Sandra DiCocco	Debt conversion	Restricted	Exempt
6/30/2020	New Issuance	500,000	Common	0.0558	no	Owen Naccarato	Employment Aghreement	Restricted	Exempt
Balance 06/30/20: Common		68,464,742							
11/22/2019	New Issuance	5,000	Preferred	no market	no	Brian Bonar	Debt	n/a	Exempt
	Series F	5,000							
Balance 06/30/20: Preferred		5,000							
Share Outstanding on Date of this Report									
<u>Ending Balance</u>									
Ending Balance									
Date: 6-30-2020		68,464,742							
Preferred:		5,000							

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
Convertible Notes							
6/30/2019	1,931,250	1,875,000	56,250	6/30/2020	.034 per share	Brian Bonar	Wages
Notes Payable							
6/30/2019	38,593	37,469	1,124	6/30/2019		Tipp Investments LLC/ Sandra Di Cicco	Loan
6/30/2019	2,318	2,250	68	6/30/2020		Trucept, Inc./ Norman Tipton	Loan
6/30/2019	1,679	1,630	49	6/30/2020		Prime Capital HR/Andrew Jones	Loan
6/30/2019	270,062	262,196	7,866	6/30/2020		Afinida/Andrew Jones	Loan
9/30/2019	134,218	131,265	2,953	9/30/2020		Afinida/Andrew Jones	Loan
9/30/2019	2,122	2,075	47	9/30/2020		Prime Capital HR/Andrew Jones	Loan
9/30/2019	3,451	3,375	76	9/30/2020		Trucept, Inc./ Norman Tipton	Loan
9/30/2019	37,188	36,370	818	9/30/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
9/30/2019	1,907	1,865	42	9/30/2020		Prime Capital HR/Andrew Jones	Loan
9/30/2019	95,233	93,137	2,096	9/30/2020		Prime Capital HR/Andrew Jones	Loan
12/31/2019	18,949	18,669	280	12/31/2019		Afinida/Andrew Jones	Loan
12/31/2019	16,407	16,165	242	12/31/2019		Prime Capital HR/Andrew Jones	Loan
12/31/2019	1,142	1,125	17	12/31/2020		Trucept, Inc./ Norman Tipton	Loan
12/31/2019	154,566	152,282	2,284	12/31/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
12/31/2019	5,348	5,269	79	12/31/2020		Prime Capital HR/Andrew Jones	Loan
12/31/2019	731,728	720,914	10,814	12/31/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
3/31/2020	235,640	233,886	1,754	3/31/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
3/31/2020	1,128	1,120	8	3/31/2020		Prime Capital HR/Andrew Jones	Loan
3/31/2020	177,060	175,742	1,318	3/31/2020		Afinida/Andrew Jones	Loan
3/31/2020	14,765	14,655	110	3/31/2020		Prime Capital HR/Andrew Jones	Loan
3/31/2020	1,174	1,165	9	3/31/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
3/31/2020	417,996	417,996	3,135	3/31/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
3/31/2020	79,866	79,866	599	3/31/2020		Prime Capital HR/Andrew Jones	Loan
3/31/2020	56,287	55,868	419	3/31/2020		Trucept, Inc./ Norman Tipton	Loan
6/30/2020	228,559	228,559	0	6/30/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
6/30/2020	131,479	131,479	0	6/30/2020		Prime Capital HR/Andrew Jones	Loan
6/30/2020	13,500	13,500	0	6/30/2020		Trucept, Inc./ Norman Tipton	Loan
6/30/2020	213,890	213,890	0	6/30/2020		Tipp Investments LLC/ Sandra Di Cicco	Loan
6/30/2020	55,467	55,467.27	0	6/30/2022		Likido's Government Loan (PPP)	Loan
4/13/2020	21,042	21,042.00	0	4/13/2022		Dalrada's PPP Loan	Loan
6/30/2020	16,708	16,707.73	0	6/30/2020		Prakat Bank Loan	Loan
Total		\$5,021,999	\$92,457				

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Eric Sherb

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Title: CPA
Relationship to Issuer: Consultant

Financial Statements are Incorporated by Reference

5) Issuer's Business, Products and Services

Dalrada, through its operating subsidiaries, Dalrada Health, Dalrada Precision, and Dalrada Technologies has set forth a company mandate focused and dedicated to identifying, addressing and solving real-world global problems by means of development and acquisition of companies and products producing innovation-focused and technologically centered solutions on a global scale. In doing so, Dalrada strives to deliver eco-sensitive next-generation science, engineering, and healthcare products and services. Dalrada intends to help those in the world less fortunate to have access to financially affordable alternative options for a better quality of life. The company and its subsidiaries feel they are positioned for stable long-term growth through intelligent acquisitions, product development, market research, sound business acumen, and established operational infrastructure.

Dalrada Health Products Corporation

Dalrada Health's focus is on the business of identifying and solving global health issues. The company is focused on developing products and services that address the unmet needs of worldwide consumers due to accessibility, affordability, or availability. Our business operations are in San Diego, CA. One of the products being produced by Dalrada Health using 3rd party manufacturers, is our Visual Inspection by Acetic Acid (VIA) basic kits, used to pre-screen for cervical cancer. The Chief Medical Officer of Dalrada Health Products is based in Bangalore, India, where we are conducting our clinical studies and gathering the required approvals to sell our products in India, and in parallel gathering requirements to market the product in other nations. The other product line developed by Dalrada Health is the GlanHealth suite of branded products to deliver safety programs for disinfection and sanitization of common harmful microorganisms. GlanHealth products are an alternative solution to alcohol-based sanitizers with attributes that are non-corrosive, non-toxic, bleach and chlorine free, safe and effective.

Dalrada Health Products Corporation – VIA Kits

Dalrada Health Products has developed a Visual Inspection with Acetic Acid (VIA) kit for early detection of cervical cancer in low-and-middle income countries. Drawing on 20+ years of obstetrics and-gynecology clinical and surgical experience, the VIA single use disposable basic kit comprises of all components for conducting VIA procedure by healthcare professionals. The contents are manufactured in FDA approved facilities, sterilized and standardized with the objective of providing reliable equipment and reagents for standardized process, preventing cross contamination and achieving consistent results. Proprietary staining methods yield enhanced resolution to enable image processing and patient diagnosis on hand-held mobile devices, with AI-based technology to proactively monitor and raise awareness about population health issues. Dalrada believes it has a competitive advantage with the VIA kit that provide immediate results, easy-of-use and accessibility, pain and discomfort free testing, and a low-cost solution. India will be the first target market, and the company is in the process of obtaining the required regulatory certifications and approvals, while conducting clinical studies in collaboration with select hospitals in India. The product's first clinical trial screened 100 women, producing 94.9% accuracy in comparison to PAP smear screening. A second clinical trial is planned to screen 200 women during the next 3-months. Additional market opportunities will target the Middle East / Asia, Africa, South America, Indonesia, Malaysia, and North America. Currently Dalrada Health Products Corporation has developed the system and methodology for the cervical cancer screening product with patents pending in India and the United States as a comprehensive healthcare solution.

Dalrada Health Products Corporation – Acquisition of Shark Innovative Technologies Corp. (“Shark”)

On or about March 23, 2020 Dalrada Health Products Corporation acquired One Hundred percent (100%) of the ownership of Shark for Shark is a cleaning solutions provider using electrostatic machines to spray and deodorize residential spaces, healthcare facilities, hospitality, transportation, manufacturing, automotive, schools/education systems, and other facilities requiring cleaning services. Through the acquisition of Shark, Dalrada Health Products developed the GlanHealth Brand (dba of Dalrada Health Products Corporation) to distribute alcohol-free hand sanitizers, surface cleaners, laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands,

and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors, vendors, and formulators for the development, sale, and marketing of its products and services.

Dalrada Precision Corporation

Dalrada Precision is focused on the acquisition of companies and development of products that allow for design, engineering, manufacturing, and distribution on a global scale. Dalrada Precision helps realize ideas from concept and delivery to after sales service, offering unique and specific solutions. At all levels and all verticals of its operations, Dalrada Precision's mandate is the development of products that lessen the burden on engineering design, manufacturing processes, regulatory demands, cost, and distribution.

Dalrada Precision Corporation – Acquisition of Likido Ltd. (HQ)

On December 6, 2019, Dalrada, via its wholly owned subsidiary, Dalrada Precision, acquired, by stock exchange agreement, one hundred percent of Likido Ltd. (HQ), a United Kingdom engineering-design company based in Edinburgh, Scotland. Likido is an international technology company, developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending) and use of supercritical CO₂, Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and the minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and enhancing quality of life through the provision of low-carbon heating and cooling systems.

Dalrada Technologies

Dalrada Technologies was formed for the purpose of acquiring and investing in various global technology related initiatives. Dalrada Technologies is focused on the creation, development, and acquisition of innovative and intelligent technologies, including platform services, software engineering services, technology consulting, and AI based solutions.

Dalrada Technologies - Prakat Solutions Inc.

On January 9, 2020 Dalrada Financial Corporation acquired seventy-two percent (72%) of the issued and outstanding common shares of Prakat Solutions, Inc. is a Texas corporation, by stock purchase agreement ("Prakat Texas"). Prakat Texas has a wholly owned subsidiary, Prakat Solutions Private Limited, a corporation formed in India with a ten (10) year operating history, ("Prakat India"). Prakat India provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization. The Prakat India team provides end to end Product Engineering services across various domains, including – Banking & Financial Services, Telecom, Retail, Healthcare, Manufacturing, Legal and IT Infrastructure. Prakat India is an ISO 9001 Certified Company.

6) Issuer's Facilities

Lease Commitments

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.

Operating lease right of use ("ROU") assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease payments are recognized as lease expense on a straight-line basis over the lease term. The Company primarily leases buildings (real estate) which are classified as

operating leases. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company's leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.

The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.

Lease payments included in the measurement of the lease liability are comprised of fixed payments, variable payments that depend on index or rate, and amounts probable to be payable under the exercise of the Company option to purchase the underlying asset if reasonably certain.

Variable lease payments not dependent on a rate or index associated with the Company's leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed as probable. Variable lease payments are presented as operating expenses in the Company's income statement in the same line item as expense arising from fixed lease payments. As of and during the year ended June 30, 2020, management determined that there were no variable lease costs.

Right of Use Asset

In May 2020, the Company entered into a five-year lease agreement to lease a commercial building in Escondido, California. The building is owned by a related party. The Company recognized a right of use asset and liability of \$822,389 and used an effective borrowing rate of 3.0% within the calculation. Imputed interest is \$53,399. The lease agreements mature in April 2025. Total amounts expensed under the lease during the year ended June 30, 2020 were \$16,245 for which is included accounts payable and accrued liabilities – related parties.

In May 2020, the Company entered into three-year lease agreement to lease a warehouse in Brownsville, Texas. The Company recognized a right of use asset and liability of \$177,124 and used an effective borrowing rate of 3.0% within the calculation. Imputed interest is \$8,399. The lease agreements mature in April 2025.

The Company's Prakat subsidiary entered into a lease agreement to lease office space through September 2026. The Company recognized a right of use asset and liability of \$140,874 and used an effective borrowing rate of 9.2% within the calculation. Imputed interest is \$86,591.

The following are the expected lease payments as of June 30, 2020, including the total amount of imputed interest related:

Fiscal Year Ended June 30,

2021	\$	264,371
2022		267,113
2023		259,215
2024		207,901
2025		194,616
Thereafter		42,237
		1,235,453

Less: imputed interest

(116,979)

Total

\$ 1,118,474

7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding any person or entity owning 5% of more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Brian Bonar	CEO and Chairman of the Board	600 La Terraza Blvd., Second Floor, Escondido, CA 92025	5,026,314	Common	7.9%	
Brian Kendrick	Director	600 La Terraza Blvd., Second Floor, Escondido, CA 92025	0			
Pauline Gourdie	Director	600 La Terraza Blvd., Second Floor, Escondido, CA 92025	0			
Fletcher Robbe	Director	600 La Terraza Blvd., Second Floor, Escondido, CA 92025	0			
Fawad Nisar	COO and Director	600 La Terraza Blvd., Second Floor, Escondido, CA 92025	3,000,000	Common	4.3%	
Harvey Hershkowitz	Director	600 La Terraza Blvd., Second Floor, Escondido, CA 92025				

8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No pending legal proceedings

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Counsel

Name: Fletcher Robbe
Firm: Fletcher Robbe International LLP Attorneys' at Law
Address 1: 468 Camden Drive, 2nd floor, Beverly hills, CA 90210

Accountant or Auditor

Name: Eric Sherb
Firm: Eric Sherb Consulting Services
Address 1: 145 West 67th St., Apt 26J, New York, NY 10023

Investor Relations Consultant

None

Other Service Providers

None

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Brian Bonar certify that:

1. I have reviewed this annual report of Dalrada Financial Corporation dated June 30, 2020;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Insert signature

/s/ Brian Bonar

Principal Executive Officer

October 16, 2020

Principal Financial Officer:

I, Brian Bonar certify that:

1. I have reviewed this Annual report of Dalrada Financial Corporation dated June 30, 2020;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Insert signature

/s/ Brian Bonar

Principal Financial Officer

October 16, 2020